person
as of 2026-07-01Robert C. Smith, MD, PhD
Robert C Smith, MDRobert C Smith, MD PhDRobert C Smith, MD, PhDRobert C. Smith, MD PHD
at a glance
Roles: Principal Investigator, Author
KOL signal score 9
1 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Nathan Kline Institute for Psychiatric Research
Roles
Principal Investigator, Author
KOL signal
9
Publications
1 (1 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
6
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
NCT00802919Phase 4Completed
Metformin for Weight Loss in Schizophrenia
NCT01177709—Terminated
Varenicline Effects In Schizophrenic Smokers
NCT00548470Phase 4Completed
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
NCT00231894Phase 4Completed
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
NCT02128919—Completed
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
NCT00287820Phase 4Completed
Publications & congress
1
Clozapine After 1 Failed Antipsychotic Drug Trial in First-Episode Psychosis: A Randomized Clinical Trial.
JAMA psychiatry · 2026 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
PRINCIPAL_INVESTIGATOR
trial